UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94
UBS analyst Joon Lee initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $94.
Share
Why It Matters
A big investment bank thinks Viking Therapeutics is worth buying. They believe the stock could reach $94 per share.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.